ARID1A and cancer: Nowadays, a diverse range of compounds holds potential benefits in ARID1A-altered cancers, including immune checkpoint blockade (PDL-1) and inhibitors of mTOR, EZH2, histone deacetylases, ATR, and/or PARP.